Skip to main content

Table 3 Substance use history of 154 participants undergoing treatment for cannabis use in New South Wales, Australia

From: The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients

Substance use Total (N = 154) SCRAs (n = 82) Cannabis (n = 72) Comparison of lifetime substance usea
(p-value)
Ever
(%)
3 month
(%)
1 month
(%)
Median
Days/28
n (IQR)
Ever
(%)
3 month
(%)
1 month
(%)
Median
Days/28
n (IQR)
Ever
(%)
3 month
(%)
1 month
(%)
Median
Days/28
n (IQR)
Cannabis 100.0 92.2 84.4 26 (18–28) 100.0 90.2 81.7 21 (4.5–26) 100.0 94.4 87.5 28 (14–28) -
SCRA 53.2 14.3 10.4 20 (1–28) 100.0 26.8 19.5 20 (1–28) 0 0 0 0 -
Alcohol 96.1 72.1 63.6 5 (2–14) 97.6 76.8 68.3 5 (2–13) 94.4 66.7 58.3 5 (3–14) 0.319
Tobacco 89.6 80.5 78.6 28 (26–28) 90.2 82.9 79.3 28 (25–28) 88.9 77.8 77.8 28 (28–28) 0.783
Amphetamines 79.2 38.3 27.3 4 (1–20) 80.5 35.4 26.8 5 (1–20) 77.8 41.7 27.8 4 (1–11) 0.679
Ecstasy 68.2 14.9 7.1 2 (1–2) 72.0 18.3 7.3 1 (1–2) 63.9 11.1 6.9 2 (1–2) 0.284
Hallucinogens 53.9 3.9 1.9 3 (2–4) 69.5 4.9 2.4 3 (2–3) 36.1 2.8 1.4 3 (3–3)  < 0.001
Cocaine 51.9 11.0 5.8 2 (2–4) 50.0 7.3 2.4 3 (3–6) 54.2 15.3 9.7 2 (2–5) 0.606
Benzodiazepines—prescribed 39.6 24.7 22.1 3 (2–7) 45.1 29.3 26.8 3 (2–6) 33.3 19.4 16.7 5 (2–7) 0.136
Opioids—prescribed 36.4 23.4 18.8 7 (4–28) 26.8 13.4 9.8 5 (2–15) 47.2 34.7 29.2 10 (5–28) 0.009
Opioids—illicit 28.6 8.4 7.1 2 (1–8) 39.0 12.2 11.0 2 (1–7) 16.7 4.2 2.8 17 (13–21) 0.002
Synthetic stimulants 19.5 2.6 0 0 32.9 3.7 0 0 4.2 1.4 0 0  < 0.001
Benzodiazepines—illicit 19.5 7.8 7.1 2 (1–4) 25.6 12.2 11.0 2 (1–4) 12.5 2.8 2.8 3 (3–3) 0.040
Inhalants 16.9 0.6 0 0 26.8 0 0 0 5.6 1.4 0 0  < 0.001
Opioid agonist treatment 7.1 2.7 2.7 28 (28–28) 9.8 3.7 3.7 28 (28–28) 4.2 1.4 1.4 28 (28–28) 0.187
Other 6.5 0.6 0.6 1 (1–1) 9.8 1.2 1.2 1 (1–1) 2.8 0 0 0 0.080
  1. aChi-square test comparisons of SCRA and cannabis groups for ever use of all substances, excluding cannabis and SCRAs